Effects of removing reimbursement restrictions on targeted therapy accessibility for non-small cell lung cancer treatment in Taiwan: an interrupted time series study

INTERVENTIONS: Targeted therapies have been proven to provide clinical benefits to patients with metastatic non-small cell lung cancer (NSCLC). Gefitinib was initially approved and reimbursed as a third-line therapy for patients with advanced NSCLC by the Taiwan National Health Insurance (NHI) in 20...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMJ Open
Hlavní autoři: Hsu, Jason C, Wei, Chen-Fang, Yang, Szu-Chun
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Publishing Group 2019
Témata:
Health Policy
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6429989/
https://ncbi.nlm.nih.gov/pubmed/30878976
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2018-022293
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky